TH — Theratechnologies Share News
0.000.00%
Last trade - 00:00- CA$205.53m
- CA$252.52m
- $85.87m
Brief: Theratechnologies Inc Says 2023 Q3 Positive Adjusted EBITDA To Be Achieved
Brief: Theratechnologies Completes 1-For-4 Reverse Stock Split
Brief: Theratechnologies Announces Amendments To Its Term Loan Facility With Affiliates Of Marathon Asset Management
Brief: Theratechnologies Announces 1-For-4 Reverse Stock Split
Canada Research Roundup: Gibson Energy, Laurentian Bank of Canada, Russel Metals
Brief: Theratechnologies Reports Second Quarter 2023 Financial Results And Business Updates
Brief: Theratechnologies To Hold Oncology Investigator Call On June 13
Theratechnologies up as FDA agrees to amended protocol for tumor drug trial
Brief: Theratechnologies Receives FDA Agreement To Amended Trial Protocol For Its Lead Pdc Candidate Sudocetaxel Zendusortide
Brief: Early Warning Report Issued Pursuant To National Instrument 62-103 - Acquisition Of Securities Of Theratechnologies Inc.
Brief: Theratechnologies Inc Confirmed That Amended Protocol For Phase 1 Clinical Trial Studying Sudocetaxel Zendusortide Has Been Filed With U.S. FDA
Canada Research Roundup: Air Canada, Cogeco Communications, MTY Food Group
Brief: Theratechnologies Receives Nasdaq Notification Letter Regarding Share Price
Brief: Theratechnologies Reports Financial Results And Business Updates For The Fourth Quarter And Full Year Fiscal 2022
Brief: Theratechnologies Announces Amendment To Its Term Loan Facility With Affiliates Of Marathon Asset Management
Brief: Theratechnologies Presents New Tesamorelin Data Demonstrating Improvement Of Metabolic Syndrome In People With HIV
Brief: Theratechnologies Announces Path To Resume Th1902 Clinical Development
Brief: Open Letter To Shareholders From CEO Paul Levesque
Brief: Taimed Biologics Says It Has Terminated Theratechnologies' Exclusive Rights Of The Company's Product Trogarzo In Europe